NCT06888817View on ClinicalTrials.gov

Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

408

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2030

Conditions
Radiation NecrosisHigh Grade Glioma (III or IV)Brain MetastasasesRadiation ToxicityRadiation EffectRadiation InjuryRadiation Injuries
Interventions
DRUG

Bevacizumab

Intravenous bevacizumab at a 600 mg flat dose every three weeks for four courses over 12 weeks

DRUG

Dexamethasone

Daily oral dexamethasone followed by a protocol-based tapering dose over 12 weeks

Trial Locations (5)

1066 CX Amsterdam

Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam

Unknown

Amsterdam University Medical Centers, location VUmc and AMC, Amsterdam

2333 ZA Leiden

Leiden University Medical Center, Leiden

2262 BA Leidschendam

Haaglanden Medical Center, The Hague

3584 CX Utrecht

University Medical Center Utrecht, Utrecht

All Listed Sponsors
collaborator

UMC Utrecht

OTHER

collaborator

Amsterdam UMC

OTHER

collaborator

Medical Center Haaglanden

OTHER

collaborator

Leiden University Medical Center

OTHER

lead

The Netherlands Cancer Institute

OTHER